Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Kidney Cancer Drugs Market

Kidney Cancer Drugs Market Share

Report ID: GMI10004
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Kidney Cancer Drugs Market Share

The kidney cancer drugs industry is led by major pharmaceutical companies like Pfizer Inc., Novartis AG, and Bayer AG, offering a range of innovative treatments such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. These companies invest heavily in research and development to address unmet medical needs and expand treatment options for kidney cancer patients. Emerging biotech firms are also making strides with promising drug candidates, capitalizing on advancements in precision medicine. With the global rise in kidney cancer cases, demand for effective treatments is increasing, driving significant growth and competition among market players, ultimately leading to improved patient outcomes.

Kidney Cancer Drugs Market Companies

Prominent players operating in the kidney cancer drugs industry include:

Active Biotech AB
Amgen, Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GSK plc
Helsinn Healthcare SA
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Kidney cancer drugs industry size was worth USD 6.2 billion in 2023 and is projected to expand at 5.6% CAGR from 2024 to 2032, attributed to the ongoing advancements in treatment modalities and increasing incidence of kidney cancer.

The RCC segment in the kidney cancer drugs industry account for USD 5.4 billion in 2023 due to the rising aging populations, lifestyle changes, and environmental exposures.

The targeted therapy segment garnered 53.6% of the kidney cancer drugs market share in 2023, as kidney cancer drugs provide enhanced understanding of the molecular biology and signaling pathways involved in kidney cancer pathogenesis.

North America kidney cancer drugs industry recorded USD 2.3 billion in revenue in 2023 and is projected to grow at 5.3% CAGR between 2024 and 2032, led by the high healthcare expenditure and growing investments in innovative therapies.